On 5 April 2024, the FDA granted accelerated, tumor-agnostic approval to trastuzumab deruxtecan (Enhertu, T-DXd) for adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who had received prior systemic therapy and lacked satisfactory treatment alternatives [102]. Here, ERBB2 is linked to neoplasm.